News | CEBINA

Latest News

28 February 2024

CEBINA announces the launch of DanubeNeuro, an acceleration program transforming insightful neuroscience research into novel therapeutics

18 December 2023

Eveliqure initiates clinical safety and immunogenicity trials of its vaccine candidate against Shigellosis and ETEC in endemic populations in Bangladesh

02 May 2023

CEBINA announces positive results of a Phase 2 Clinical Study with COVID-19 patients and Azelastine nasal spray published in a peer-reviewed scientific journal

Get in touch

We're here to collaborate and innovate -

+43 (0)1 9092208

info@cebina.eu

12 September 2023 - Danube Labs: Call for Proposals - September 2023
02 May 2023 - CEBINA Announces Positive Results of a Phase 2 Clinical Study with COVID-19 patients and Azelastine Nasal Spray Published in a Peer-Reviewed Scientific Journal
07 March 2023 - Danube Labs: Call for Proposals - April 2023
04 July 2022 - CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2
19 April 2022 - Danube Labs: Call for Proposals
23 February 2022 - Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC
03 February 2022 - Azelastine - the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of SARS-CoV-2
10 December 2021 - CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
17 August 2021 - Widely available anti-allergy azelastine nasal spray poised to revolutionize COVID-19 management
14 June 2021 - CEBINA announces the launch of Danube Labs, a partnership with Evotec to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions
04 May 2021 - CEBINA reports potency of azelastine against emerging dominant variants of SARS-CoV-2 in laboratory testing
17 February 2021 - URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19
19 November 2020 - Eveliqure announces the publication of key preclinical data for its clinical stage vaccine candidate against Shigellosis and ETEC
24 September 2020 - Eveliqure announces the initiation of a Phase 1 clinical study of its combined Shigella and ETEC vaccine candidate
17 September 2020 - CEBINA reports positive findings on the potency of azelastine, a widely used anti-histamine, as anti-COVID-19 approach
09 September 2020 - Eveliqure announces the award of a NIAID contract to finance Phase 2 clinical studies of its combined Shigella and ETEC vaccine candidate
9 July 2020 - CEBINA identifies a common antihistamine nasal spray as a potential anti-COVID-19 approach
30 June 2020 - Eveliqure secures further private investment to support development of its combined Shigella and ETEC vaccine candidate
4 June 2020 - CEBINA secures seed funding for its unique extended spectrum Coronavirus vaccine
2 June 2020 - Eveliqure Biotechnologies announces regulatory approval to initiate first clinical trial of its ShigETEC vaccine candidate Biotechnologies
20 April 2020 - Calyxha Biotechnologies announces grant of a European Patent on neurodegenerative diseases
17 April 2020 - CEBINA today announces the initiation of several collaborative projects that address the global health crisis caused by the pandemic spread of the SARS-CoV-2 virus
4 March 2020 - Calyxha Biotechnologies announces new financing to support pre-clinical development of its therapeutic lead candidate, CAL-X
5 November 2019 - Eveliqure Biotechnologies GmbH announces a grant from the Wellcome Trust to support their effort to develop a Shigella-ETEC combination vaccine for travelers and children in resource poor countries

Previous News

Publications

Antiviral Potential of Azelastine against Major Respiratory Viruses, Fischhuber et al
Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients, Klussmann et al
Anti-Toxin Responses to Natural Enterotoxigenic Escherichia coli (ETEC) Infection in Adults and Children in Bangladesh, Girardi et al
Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial, Girardi et al
The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue, Konrat et al
Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC, Harutyunyan et al